Eye Care Physicians

A Potential Breakthrough Diagnostic for Early Detection of AMD

The AdaptDx™ is under development as a new diagnostic tool to aid in the early detection of AMD.

Learn More


Advanced Dark Adaptometer
Expands Research Capabilities

The AdaptDx™ dark adaptometer provides researchers with a powerful new tool to study visual function and ocular diseases.

Learn More

Pharmaceutical Companies

Support for Next Generation
AMD Drug Development

Dark adaptation provides a more sensitive clinical endpoint in trials of drugs for AMD.

Learn More


Early Detection of AMD
is Beneficial

Early detection allows early intervention to preserve vision and improve quality of life.

Learn More

Dark Adaptation

Age-related macular degeneration (AMD) is a progressive eye disease and a leading cause of blindness, affecting 13 million people in the U.S. alone. It impacts the retina of the eye, in an area called the macula where detailed central vision occurs. There is a strong, well-understood correlation between AMD and dark adaptation, which measures how quickly an individual recovers vision when going from bright light to darkness.

Learn More

The AdaptDx® has the potential to be the first practical diagnostic for early detection and tracking of AMD. It is being developed to provide doctors with an easy-to-use, functional test that will allow them to intervene at the earliest possible time, preventing vision loss and improving quality of life.

Learn More

Preserving Vision Before It's Too Late

Gregory R. Jackson, PhD, Associate Professor of Ophthalmology at Penn State College of Medicine, discusses the promise of the AdaptDx as a test for age-related macular degeneration (AMD), a disorder that affects millions of people, and often goes undiagnosed for years.

Watch Now

The AdaptDx is cleared for sale as a dark adaptometer by the U.S. Food and Drug Administration. It is under development
as a diagnostic for AMD but is not cleared for sale as such by the U.S. FDA or any other country’s regulatory authority.